Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Jun 1, 2013 in Breast cancer | 0 comments

In a nutshell

This study evaluated the efficacy of hormone therapy in patients with two types of breast cancer, invasive ductal breast carcinomas (IDC) and invasive lobular breast carcinomas (ILC) based on hormonal status. 

Some background

Breasts are made up of lobules (milk-producing glands) and ducts (tubes that carry the milk to the nipple) surrounded by glandular and fatty tissue. IDC is cancer that begins in the milk ducts but spreads (invades) into the surrounding breast tissue. ILC is cancer that begins in the lobules of the breast and invades the surrounding breast tissue. Some types of breast cancer need estrogen (female sex hormone) to grow. These cancer cells respond to estrogen via its receptor (a protein found on the surface of the cancer cells). They are called estrogen receptor-positve (ER+ breast cancers). Breast cancers that do not need estrogen to grow are called estrogen receptor-negative (ER-). Hormone therapy is usually given to ER+ breast cancer patients to stop the cancer from growing. Tamoxifen (Nolvadex) prevents estrogen from binding its receptor on cancer cells and stops them from growing. Exemestane (Aromasin) decreases the amount of estrogen the body produces, therefore slowing or stopping the cancers growth.  

Methods & findings

This phase 3 clinical trial included overall 2603 patients with either IDC (82%) or with ILC (18%). Patients were divided into two treatment groups. Patients in group one were treated with exemestane daily for 5 years and patients in the second group were treated with tamoxifen for 3 years followed by exemestane for 2 years. For all patients a pathologist determined the hormonal status (if the cancer is ER+ or ER-).

After 5 years of treatment, relapse free survival or RFS (defined as the percentage of patients surviving without the cancer returning after a time from treatment) was 86% for patients with IDC and 83% for those with ILC. Efficacy for both hormone treatments was similar in patients with ILC and IDC. However, patients with ER+ breast cancer treated with exemestane alone had showed a 30% improved RFS compared with patients who received tamoxifen and exemestane. In contrast, patients with ER- breast cancer had better outcomes with tamoxifen and exemestane therapy. 

The bottom line

In summary, this research showed that hormone therapy had similar efficacy for both IDC and ILC patients. However, the hormonal status of the cancer influenced the outcomes of these patients. 

The fine print

This study was funded by Pfizer, the manufacturer of Aromasin.  
Published By :

European journal of cancer

Date :

Sep 03, 2012

Original Title :

Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer – A TEAM study analysis

click here to get personalized updates